Publications by authors named "Timothy Eley"

Claim this Profile
P
Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.
Angela M Lam, Nagraj Mani, Andrzej Ardzinski, Kim Stever, Andrea Cuconati, Timothy Eley

Antiviral Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.
Man-Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, Sang Hoon Ahn, Tawesak Tanwandee, Timothy Eley

Hepatol Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Yash Gandhi, Timothy Eley, Aberra Fura, Wenying Li, Richard J Bertz

Clin Pharmacokinet· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Heather Sevinsky, Luna Zaru, Reena Wang, Xiaohui Xu, Cheryl Pikora, Timothy Eley

Pediatr Infect Dis J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
Li Zhu, Hanbin Li, Phyllis Chan, Timothy Eley, Yash Gandhi

Infect Dis Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
Tushar Garimella, Xiaolu Tao, Karen Sims, Yi-Ting Chang, Jignasa Rana, Timothy Eley

Drugs R D· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
Phyllis Chan, Hanbin Li, Li Zhu, Marc Bifano, Timothy Eley

Clin Pharmacokinet· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, Juan Berenguer, Natalia Zakharova, Timothy Eley

Hepatol Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.
Timothy Eley, Tushar Garimella, Wenying Li, Richard J Bertz

Clin Pharmacol Drug Dev· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Daclatasvir Drug-Drug Interactions.
Tushar Garimella, Xiaoli You, Reena Wang, Shu-Pang Huang, Hamza Kandoussi, Timothy Eley

Adv Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans.
Jiachang Gong, Timothy Eley, Bing He, Vinod Arora, Thomas Philip

Xenobiotica· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
Lisa L Ross, Ivy H Song, Niki Arya, Mike Choukour, Jian Zong, Timothy Eley

BMC Infect Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Gregory T Everson, Karen D Sims, Paul J Thuluvath, Eric Lawitz, Tarek Hassanein, Timothy Eley

Liver Int· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies.
Hamza Kandoussi, Hao Jiang, Jianing Zeng, Naiyu Zheng, Pathanjali Kadiyala, Timothy Eley

J Pharm Biomed Anal· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Timothy Eley, Tushar Garimella, Wenying Li, Richard J Bertz

Clin Pharmacokinet· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Timothy Eley, Bing He, Ih Chang, Elizabeth Colston, Michael Child

Antivir Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative determination of free/bound atazanavir via high-throughput equilibrium dialysis and LC-MS/MS, and the application in ex vivo samples.
Xiaohui Sophia Xu, Anne Rose, Roger Demers, Timothy Eley, John Ryan

Bioanalysis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine.
Hao Jiang, Roger Demers, Hamza Kandoussi, Richard Burrell, Timothy Eley

J Pharm Biomed Anal· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Hao Jiang, Hamza Kandoussi, Jianing Zeng, Jian Wang, Roger Demers, Timothy Eley

J Pharm Biomed Anal· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Jean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, Paul J Thuluvath, Fernando Bessone, Timothy Eley

J Hepatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Timothy Eley, Heather Sevinsky, Shu-Pang Huang, Bing He, Kurt Zhu

Clin Drug Investig· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Timothy Eley

Hepatology· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
Karen D Sims, Julie Lemm, Timothy Eley, Menping Liu, Anna Berglind

Antimicrob Agents Chemother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From bench to humans: formulation development of a poorly water soluble drug to mitigate food effect.
Preetanshu Pandey, Rhye Hamey, Dilbir S Bindra, Zongyun Huang, Neil Mathias, Timothy Eley

AAPS PharmSciTech· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Anna S Lok, David F Gardiner, Christophe Hézode, Eric J Lawitz, Marc Bourlière, Timothy Eley

J Hepatol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis